The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation …
SI Jaggar, S Sellaturay, ASC Rice - Neuroscience letters, 1998 - Elsevier
SI Jaggar, S Sellaturay, ASC Rice
Neuroscience letters, 1998•ElsevierAnandamide, an endogenous ligand at the CB1 cannabinoid receptor and
palmitoylethanolamide (a putative endogenous ligand at the CB2 receptor) have both been
shown to possess anti-hyperalgesic properties in models of somatic and visceral
inflammation. In the turpentine-inflamed rat urinary bladder a reversal of the inflammation-
associated viscero-visceral hyper-reflexia (VVH) was observed when the cannabinoids were
administered 135 min after the induction of inflammation. Therefore, in this study we …
palmitoylethanolamide (a putative endogenous ligand at the CB2 receptor) have both been
shown to possess anti-hyperalgesic properties in models of somatic and visceral
inflammation. In the turpentine-inflamed rat urinary bladder a reversal of the inflammation-
associated viscero-visceral hyper-reflexia (VVH) was observed when the cannabinoids were
administered 135 min after the induction of inflammation. Therefore, in this study we …
Anandamide, an endogenous ligand at the CB1 cannabinoid receptor and palmitoylethanolamide (a putative endogenous ligand at the CB2 receptor) have both been shown to possess anti-hyperalgesic properties in models of somatic and visceral inflammation. In the turpentine-inflamed rat urinary bladder a reversal of the inflammation-associated viscero-visceral hyper-reflexia (VVH) was observed when the cannabinoids were administered 135 min after the induction of inflammation. Therefore, in this study we determined the efficacy of these two N-acylethanolamides in the prevention of VVH in the same model, using a prophylactic dosing regimen. Palmitoylethanolamide did not prevent the VVH (in the dose range 10–30 mg/kg, i.a), but anandamide attenuated the response in a dose related manner, with a threshold of 25 mg/kg (i.a). These findings provide further support for an acute anti-nociceptive and anti-hyperalgesic role for CB1 receptor agonists, with CB2 agonist effects only becoming important once the effects of inflammation are established.
Elsevier